Increased serum Neurofilament light chain levels in Parkinson’s Disease patients carrying the p.A53T SNCA mutation: Data from the PPMI study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction
Serum neurofilament light chain (NfL) levels, a marker of axonal damage, are generally elevated in neurodegenerative conditions, but results in idiopathic Parkinson’s Disease (iPD) have been inconsistent. The p.A53T mutation in the SNCA gene usually leads to a severe, rapidly progressing genetic form of PD.
Objectives
Assessing the possible use of serum NfL as a marker of ongoind neurodegeneration in A53T-PD.
Methods
Using a propensity score matching based technique with data from the Parkinson’s Progression Markers Initiative, A53T-PD participants were matched, in a 3:1 ratio, to iPD patients and healthy controls by age and disease duration, where applicable.
Results
After matching, 18 A53T-PD, 54 iPD, and 54 controls were analyzed. Serum NfL was significantly higher in A53T-PD (9.82 [8.02-18.1] pg/ml) compared to HC (7.54 [5.76-10.1]) or iPD (8.59 [6.86-11.1]) [overall p=0.049].
Conclusion
The increase in serum NfL points to a more aggressive neurodegenerative process in A53T-PD compared to iPD. This finding may help design and implement Disease-modifying treatments (DMTs) in this select group of prototypical genetic PD.
